FAQ on CNS Pharmaceuticals Inc.'s $5 Million Public Offering

What is CNS Pharmaceuticals Inc.’s recent public offering about?

CNS Pharmaceuticals Inc. has priced a public offering to raise approximately $5 million by selling 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to a single healthcare-focused institutional investor.

Why is CNS Pharmaceuticals Inc.’s public offering significant?

The offering is significant as it provides CNS Pharmaceuticals Inc. with approximately $5 million in gross proceeds for working capital and general corporate purposes, supporting its pipeline of anti-cancer drug candidates.

How does the public offering work?

The offering involves selling shares and warrants to an institutional investor, with A.G.P./Alliance Global Partners acting as the sole placement agent. The warrants allow the purchase of an equal number of shares at $1.14 per share, exercisable immediately and valid for five years.

Who is involved in CNS Pharmaceuticals Inc.’s public offering?

The offering involves CNS Pharmaceuticals Inc., a healthcare-focused institutional investor, and A.G.P./Alliance Global Partners as the sole placement agent.

When is the closing of the public offering expected?

The closing of the public offering is expected on or about May 14, 2025.

What will the proceeds of the offering be used for?

The proceeds from the offering will be used for working capital and general corporate purposes.

What is CNS Pharmaceuticals Inc.’s focus?

CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

What is CNS Pharmaceuticals Inc.’s lead drug candidate?

The company’s lead drug candidate is Berubicin, a novel anthracycline currently in development for treating serious brain and CNS oncology indications, including glioblastoma multiforme (GBM).

Where can I find more information about CNS Pharmaceuticals Inc.?

More information about CNS Pharmaceuticals Inc. can be found on their website at www.CNSPharma.com and in the company’s newsroom at https://ibn.fm/CNSP.

Who do I contact if I want more information about the public offering?

For more information about the public offering, you can visit the full press release at https://ibn.fm/olurM or contact A.G.P./Alliance Global Partners, the sole placement agent for the offering.